Publisher： Bentham Science Publishers
E-ISSN： 2212-2710|4|1|75-81
ISSN： 1872-213X
Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.4, Iss.1, 2010-01, pp. : 75-81
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase associated with the common gamma chain that is activated by multiple T-cell growth factors including IL-2, -4, -9, -15, and -21. From the recent reports, genetic absence or ablation of JAK3 is associated with defective T-cell immunity that results in severe combined immunodeficiency (SCID) and pharmacological inhibition has prolonged allograft survival in some models of organ transplantation. This review would provide an overview of some patents along with the role of JAK3 in the immune system and efficacy of JAK3 inhibitors in experimental allograft rejection and autoimmune disease.
Related content
Access to resources
Recommend
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 2, 2007-06 ,pp. :